Prokaryotics and Basilea enter collaboration to develop a novel broad-spectrum antifungal for severe invasive infections
PR Newswire —
UNION, N.J., Jan. 7, 2026 /PRNewswire/ -- Prokaryotics Inc., a privately-held biopharmaceutical company engaged in the discovery and development of novel anti-infectives, today announced an agreement with Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage...